Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5957360 | 0.89 | MMP13 (0.74) | MMP13SMN1; SMN2KDM4EKMT2ANPSR1 | |
| SCHEMBL5957461 | 0.87 | MMP13 (1.00) | MMP13SMN1; SMN2KDM4EKMT2ANPSR1 | |
| SCHEMBL5957700 | 0.83 | MMP13 (0.66) | MMP13SMN1; SMN2KDM4EKMT2ATRPA1 | |
| SCHEMBL5957475 | 0.82 | MMP13 (0.88) | MMP13SMN1; SMN2KDM4EKMT2ANPSR1 | |
| SCHEMBL5957708 | 0.81 | MMP13 (0.67) | MMP13SMN1; SMN2KDM4EKMT2ATRPA1 | |
| Hydrochloric Acid SCHEMBL5957471 | 0.81 | MMP13 (0.86) | MMP13SMN1; SMN2KDM4EKMT2ANPSR1 | |
| SCHEMBL7012216 | 0.80 | MMP13 (0.61) | MMP13SMN1; SMN2KDM4EKMT2ATRPA1 | |
| SCHEMBL5957834 | 0.79 | MMP13 (0.61) | MMP13SMN1; SMN2KDM4EKMT2ATRPA1 | |
| SCHEMBL7106604 | 0.79 | MMP13 (0.60) | MMP13SMN1; SMN2KDM4EKMT2ANPSR1 | |
| SCHEMBL5957426 | 0.78 | TRPA1 (0.67) | MMP13SMN1; SMN2KDM4EKMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060040957-A1 | BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY | 2006-02-23 | — | — | US | disclosed |
| EP-1361873-A4 | MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20050004126-A1 | Method of determining potential allosterically-binding matrix metalloproteinase inhibitors | ANDRIANJARA CHARLES (FR) | 2005-01-06 | — | — | US | disclosed |
| EP-1362054-A1 | BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-11-19 | — | — | EP | disclosed |
| EP-1361873-A2 | MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-11-19 | — | — | EP | disclosed |
| US-20030078276-A1 | Matrix metalloproteinase inhibitors | ANDRIANJARA CHARLES (FR) | 2003-04-24 | — | — | US | disclosed |
| WO-2002064080-A2 | MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LCC (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002064599-A1 | BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040957-A1 | BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS | MMP13, MMP25, MMP15 | MMP13 1/4885SMN1; SMN2 1727/4885KDM4E 1506/4885 |
| US-20050004126-A1 | Method of determining potential allosterically-binding matrix metalloproteinase inhibitors | MMP13, MMP12, MMP25 | MMP13 1/4885SMN1; SMN2 1854/4885KDM4E 2484/4885 |
| US-20030078276-A1 | Matrix metalloproteinase inhibitors | MMP13, MMP25, MMP12 | MMP13 1/4885SMN1; SMN2 1745/4885KDM4E 2733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.